Cancer-related deep venous thrombosis: Clinical importance, treatment challenges, and management strategies

Seminars in Thrombosis and Hemostasis

Volumn 29, Issue 3, 2003, Pages 247-258

  Deitcher, Steven R ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Dept of Hematol/Medical Oncology   (United States)

Author keywords

Cancer; Heparin; Hypercoagulability; Thrombosis; Warfarin

Indexed keywords

ACUTE PHASE PROTEIN; ANTINEOPLASTIC AGENT; HEPARIN; WARFARIN;

ANGIOGENESIS; ANTIANGIOGENESIS; ANTICOAGULATION; BLEEDING; CANCER; CANCER MORTALITY; CANCER PATIENT; CANCER THERAPY; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; HEPARIN INDUCED THROMBOCYTOPENIA; HEPARIN RESISTANCE; HUMAN; HYPERCOAGULABILITY; INTERNATIONAL STANDARD UNIT; LUNG EMBOLISM; METASTASIS; METASTASIS PREVENTION; MORBIDITY; PRIORITY JOURNAL; PROTEIN BINDING; RECURRENCE RISK; REVIEW; THROMBOCYTOPENIA; TREATMENT FAILURE; VASCULAR ACCESS; VEIN THROMBOSIS; VENOUS THROMBOEMBOLIC DISEASE;

ANTICOAGULANTS; DISEASE MANAGEMENT; HUMANS; NEOPLASMS; THROMBOPHILIA; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 0038817722     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-40963     Document Type: Review

References (121)

1. Prandoni P, Piccioli A, Girolami A. Cancer and venous thromboembolism: an overview. Haematologica 1999;84:437-445
2. Brill-Edwards P, Ginsberg JS, Johnston M, Hirsh J. Establishing a therapeutic range for heparin therapy. Ann Intern Med 1993;119:104-109
3. Kakkar VV, Howe CT, Nicolaides AN, Renney JT, Clarke MB. Deep vein thrombosis of the leg. Is there a "high risk" group? Am J Surg 1970;120:527-530
4. Walsh JJ, Bonnar J, Wright FW. A study of pulmonary embolism and deep leg vein thrombosis after major gynaecological surgery using labeled fibrinogen-phlebography and lung scanning. J Obstet Gynaecol Br Commonw 1974;81:311-316
5. Piccioli A, Prandoni P, Ewenstein BM, Goldhaber SZ. Cancer and venous thromboembolism. Am Heart J 1996;132:850-855
6. Gomes MPV, Deitcher SR. Diagnosis of venous thromboembolic disease in cancer patients. Oncology 2003;17:126-139
7. Sorensen HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 1998;338:1169-1173
8. Deitcher SR, Goldman CK, Ruiter K. Vascular endothelial growth factor (VEGF) levels in patients with idiopathic acute proximal deep venous thrombosis. Thromb Haemost 2001;86 (Suppl):P1517 (Abst)
9. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: risk analysis using Medicare claims data. Medicine 1999;78:285-291
10. Ottinger H, Belka C, Kozole G, et al. Deep venous thrombosis and pulmonary embolism in high-grade non Hodgkin's lymphoma: incidence, causes and prognostic relevance. Eur J Haematol 1995;54:186-194
11. Levine MN. Prevention of thrombotic disorders in cancer patients undergoing chemotherapy. Thromb Haemost 1997;78:33-136
12. Edwards RL, Silver J, Rickles FR. Human tumor procoagulants: Registry of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee, International Society on Thrombosis and Haemostasis. Thromb Haemost 1993;69:205-213
13. Falanga A, Donati MB. Pathogenesis of thrombosis in patients with malignancy. Int J Hematol 2001;73:137-144
14. Gordon S. Cancer cell procoagulants and their implications. Hematol Oncol Clin North Am 1992;6:1359-1374
15. Rickles FR, Hair GA, Zeff RA, Lee E, Bona RD. Tissue factor expression in human leukocytes and tumor cells. Thromb Haemost 1995;74:391-395
16. Bevilacqua MP, Pober JS, Majeau GR, et al. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin-1. Proc Natl Acad Sci USA 1996;83:4533-4537
17. Deitcher SR, Carman TL, Sheikj M, Gomes M. Hypercoagulable syndromes: evaluation and management strategies in acute limb ischemia. Semin Vasc Surg 2001;14:74-85
18. Deitcher SR, Lucore C, Eisenberg PR. Impaired resolution of a massive pulmonary embolus associated with an impaired fibrinolytic response. Am J Med 1994;96:483-484
19. Deitcher SR, Erban JK, Limentani SA. Acquired free protein S deficiency asociated with multiple myeloma. Am J Hematol 1996;51:319-323
20. Anderson AJ, Krasnow SH, Boyer MW, et al. Thrombosis: the major Hickman catheter complication in patients with solid tumor. Chest 1989;95:71-75
21. Bona RD. Thrombotic complication of central catheters in cancer patients. Semin Thromb Hemost 1999;25:147-157
22. Gould JR, Carloss HW, Skinner WL. Groshong catheter-associated subclavian venous thrombosis. Am J Med 1993;95:419-423
23. Kee ST, Kinoshita L, Razavi MK, et al. Superior vena cava syndrome: treatment with catheter-directed thrombolysis and endovascular stent placement. Radiology 1998;206:187-193
24. Patel V, Igwebe T, Mast H, Karetzky MS. Superior vena cava syndrome; current concepts of management. N Engl J Med 1995;92:245-248
25. Prandoni P, Polistena P, Bernardi E, et al. Upper extremity deep vein thrombosis. Risk factors, diagnosis, and complications. Arch Intern Med 1997;157:57-62
26. Raad II, Luna M, Khalil SA, et al. The relationship between the thrombotic and infectious complications of central venous catheters. JAMA 1994;271:1014-1016
27. Goodnough LT, Saito H, Manni A, Jones PK, Pearson OH. Increased incidence of thromboembolism in stage-4 breast cancer patients treated with a five-drug chemotherapy regimen: a study of 159 patients. Cancer 1984;54:1264-1268
28. Gail MH, Costantino JP, Bryant J, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999;91:1829-1846
29. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991;9:286-294
30. Levine MN, Gent M, Hirsh J, et al. The thrombogenic effect of anticancer drug therapy in women with stage-2 breast cancer. N Engl J Med 1988;318:404-407
31. Pritchard KI, Paterson AH, Paul NA, et al. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol 1996;14:2731-2737
32. Zangari M, Siegel E, Anaissie E, et al. Risk factors for deep vein thrombosis in a large group of myeloma patients treated with thalidomide: The Arkansas Experience. Blood 2001;98:161a (Abst)
33. Deitcher SR, Carman TL. Deep venous thrombosis and pulmonary embolism. Curr Treatment Options Cardiovasc Med 2002;4:223-238
34. Scates SM. Diagnosis and treatment of cancer-related thrombosis. Hematol Oncol Clin North Am 1992;6:1329-1339
35. Breddin HK, Hach-Wunderle V, Nakov R, Kakkar VV. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. N Engl J Med 2001;344:626-631
36. Krauth D, Holden A, Knapic N, Liepman M, Ansell J. Safety and efficacy of long-term oral anticoagulation in cancer patients. Cancer 1987;59:983-985
37. Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism. A population-based chohort study. Arch Intern Med 2000;160:761-768
38. Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 2000;160:769-774
39. Prandoni P, Lensing AW, Cogo A, et al. The long term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1-7
40. Prandoni P. Antithrombotic strategies in patients with cancer. Thromb Haemost 1997;78:141-144
41. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484-3488
42. Bona RD, Sivjee KY, Hickey AD, Wallace SB, Wajcs SB. The efficacy and safety of oral anticoagulation in patients with cancer. Thromb Haemost 1995;74:1055-1058
43. Bona RD, Hickey AD, Wallace DM. Efficacy and safety of oral anticoagulation in patients with cancer. Thromb Haemost 1997;78:137-140
44. Hutten BA, Prins MH, Gent M, et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000;8:3078-3083
45. Levine MN, Hirsh J, Gent M, et al. A randomized trial comparing activated partial thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994;154:49-56
46. Hirsh J, Warkentin TW, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin; mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 2001;119(Suppl):64S-94S
47. Chan A, Woodruff RK. Complications and failure of anticoagulation therapy in treatment of venous thromboembolism in patients with disseminated malignancy. Aust N Z J Med 1992;22:119-122
48. Deitcher SR. Interpretation of the international normalized ratio in patients with liver disease. Lancet 2002;359:47-48
49. Hirsh J, Dalen JE, Anderson D, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001;119(Suppl):8S-21S
50. Wells PS, Holbrook AM, Crowther NR, et al. The interaction of warfarin with drugs and food: a critical review of the literature. Ann Intern Med 1994;121:676-683
51. Deitcher SR, Carman TL. Heparin induced thrombocytopenia: natural history, diagnosis, and management. Vasc Med 2001;6:113-119
52. Levine MN, Lee AY, Baker RI, et al. A randomized trial of long-term dalteparin low molecular weight heparin versus oral anticoagulant therapy in cancer patients with venous thromboembolism. Blood 2002;100:82a (Abstract 298)
53. Deitcher, SR, Kessler, CM, Merli G, Rigas J, Lyons RM, Cort S. Secondary prevention of venous thromboembolic events in patients with active malignancy: A randomized study of enoxaparin sodium alone versus initial enoxaparin sodium followed by warfarin for a 180-day period. American Society of Clinical Oncology 2003
54. Beyth RJ, Quinn LM, Landefeld S. Prospective evaluation of an index for predicting the risk of major bleeding risk outpatients treated with warfarin. Am J Med 1998;105:91-99
55. Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest 2001;119(Suppl):108S-121S
56. Gitter MJ, Jaeger TM, Petterson TM, Gersh MD, Silverstein MD. Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota. Mayo Clin Proc 1995;70:725-733
57. Wester JPJ, de Valk HW, Nieuwenhuis HK, et al. Risk factors for bleeding during treatment of acute venous thromboembolism. Thromb Haemost 1996;76:682-688
58. Melissari E, Parker CJ, Wilson NV, et al. Use of low molecular weight heparin in pregnancy. Thromb Haemost 1992;68:652-656
59. Sanson B-J, Lensing AW, Prins MH, et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 1999;81:668-672
60. Nelson-Piercy C, Letsky EA, de Swiet M. Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk. Am J Obstet Gynecol 1997;176:1062-1068
61. Shaughnessy SG, Young E, Deschamps P, Hirsh J. The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. Blood 1995;86:1368-1373
62. Muir JM, Hirsh J, Weitz JI, et al. A histomorphometric comparison of the effects of heparin and low molecular weight heparin on cancellous bone in rats. Blood 1997;89:3236-3242
63. Bhandari M, Hirsh J, Weitz J, et al. The effects of standard and low molecular weight heparin on bone nodule formation in vitro. Thromb Haemost 1998;80:413-417
64. Carman TL, Kanner AA, Barnett GH, Deitcher SR. Neurosurgery thromboprophylaxis following tumor surgery: a survey. South Med J 2003;96:17-22
65. Altschuler E, Moosa H, Selker RG, Vertosick FT. The risk and efficacy of anticoagulant therapy in the treatment of thromboembolic complications in patients with primary malignant brain tumors. Neurosurgery 1990;27:74-771
66. Choucair AK, Silver P, Levin VA. Risk of intracranial hemorrhage in glioma patients receiving anticoagulant therapy for venous thromboembolism. J Neurosurg 1987;66:357-358
67. Norris LK, Grossman SA. Treatment of thromboembolic complications in patients with brain tumors. J Neurooncol 1994;22:127-137
68. Olin JW, Young JR, Graor RA, et al. Treatment of deep vein thrombosis and pulmonary emboli in patients with primary and metastatic brain tumors. Arch Intern Med 1987;147:2177-2179
69. Ruff RL, Posner JB. Incidence and treatment of peripheral venous thrombosis in patients with glioma. Ann Neurol 1983;13:334-336
70. Schiff D, DeAngelis LM. Therapy of venous thromboembolism in patients with brain metastases. Cancer 1994;73:493-498
71. Levine M, Gent M, Hirsch J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334:677-681
72. Koopman MM, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996;334:682-687
73. Hull RD, Raskob GL, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis. N Engl J Med 1992;326:975-982
74. Lindmarker P, Holmstrom M, Granqvist S, et al. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1994;72:186-190
75. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997;337:657-662
76. Weitz JI. Low molecular weight heparins. N Engl J Med 1995;337:688-698
77. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-1335
78. Lensing AW, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low molecular weight heparins. A meta-analysis. Arch Intern Med 1995;155:601-607
79. Siragusa S, Cosmi B, Piovella, Hirsh J, Ginsberg JS. Low molecular weight heparins and unfractionated heparin in the treatment of patient with acute venous thromboembolism; results of a meta-analysis. Am J Med 1996;100:269-277
80. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a meta-analysis of randomized, controlled trails. Ann Intern Med 1999;130:800-809
81. Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000;160:181-188
82. Green D, Hull RD, Brant R, Pineo GF. Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet 1992;339:1476
83. Folkman J, Langer R, Linhardt RJ, Haudenschild C, Taylor S. Angiogenesis inhibition and tumour regression caused by heparin or heparin fragment in the presence of cortisone. Science 1983;221:719-725
84. Norrby K. Heparin and angiogenesis: a low-molecular-weight fraction inhibits and a high-molecular-weight fraction stimulates angiogenesis systemically. Haemostasis 1993;23(Suppl):141-149
85. Hyers TM, Agnelli A, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001;119 (Suppl):176S-193S
86. Anand SS, Bates S, Ginsberg JS, et al. Recurrent venous thrombosis and heparin therapy; an evaluation of the importance of early activated partial thromboplastin times. Arch Intern Med 1999;159:2029-2032
87. Hull RD, Raskob GE, Brant RF, Pineo GF, Valentine KA. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med 1997;157:2562-2568
88. Raschke RA, Reilly BM, Guidry JR, et al. The weight-based heparin dosing nomogram compared with a standard care nomogram: a randomized, controlled trial. Ann Intern Med 1993;119:874-881
89. Merli G, Spiro TE, Olsson C-G, et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 2001;134:191-202
90. Hainer JW, Barrett JS, Assaid CA, et al. Dosing in heavyweight/obese patients with the LMWH, tinzaparin: A pharmacodynamic study. Thromb Haemost 2002;87:817-823
91. Moll S, Ortel TL. Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med 1997;127:177-185
92. Harrison L, Johnston M, Massicotte MP, et al. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 1997;126:133-136
93. Fihn SD, McDonell M, Martin D, et al. Risk factors for complications of chronic anticoagulation. Ann Intern Med 1993;118:511-520
94. Choueiri T, Deitcher SR. Why shouldn't we solely use warfarin to treat acute venous thrombosis? Cleveland Clin J Med 2002;69:546-548
95. Monreal M, Lafoz E, Olive A, del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 1994;71:7-11
96. Pini M, Aiello S, Manotti C, et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost 1994;72:191-197
97. Das SK, Cohen AT, Edmondson RA, Melissari E, Kakkar W. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World J Surg 1996;20:521-527
98. Loaciuk S, Bielska-Falda H, Nosczyk W, et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thromb Haemost 1999;81:26-31
99. Hull RD, Pineo GF, Mah AF, Brant RF. A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Blood 2002;100:148a (Abstract 556)
100. Gruel Y, Meyer G, Marjanovic Z, et al. Canthanox, a randomized controlled study comparing low molecular weight heparin and warfarin for the prevention of recurrent venous thromboembolism in patients with cancer. Blood 2001;98:707a (Abst)
101. Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995;332:1661-1665
102. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999;340:901-907
103. Schulman S, Granqvist S, Holström M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997;336:393-398
104. Zacharski LR, Henderson WG, Rickles FR, et al. Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Study No. 75. JAMA 1981;245:831-835
105. Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism: Duration of anticoagulation trial. N Engl J Med 2000;342:1953-1958
106. Simonneau G, Sors H, Charbonnier B, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997;337:663-669
107. Goldhaber SZ. Thrombolysis in pulmonary embolism: a debatable indication. Thromb Haemost 2001;86:444-451
108. Arcasoy SM, Kreit JW. Thrombolytic therapy of pulmonary embolism: a comprehensive review of current evidence. Chest 1999;115:1695-1707
109. Konstantinides S, Tiede N, Geibel A, et al. Comparison of alteplase versus heparin for resolution of major pulmonary embolism. Am J Cardiol 1998;82:966-970
110. Kanter DS, Mikkola KM, Patel SR, Parker SZ, Golhaber SZ. Thrombolytic therapy for pulmonary embolism: frequency of intracranial hemorrhage and associated risk factors. Chest 1997;111:1241-1245
111. Balestreri L, De Cicco M, Matovic M, Coran F, Morassut S. Central venous catheter-related thrombosis in clinically asymptomatic oncology patients: a phlebographic study. Eur J Radiol 1995;20:108-111
112. Monreal M, Raventos A, Lerma R, et al. Pulmonary embolism in patients with upper extremity DVT associated to venous central lines - a prospective study. Thromb Haemost 1994;72:548-550
113. Ault M, Artal R. Upper extremity DVT: what is the risk? Arch Intern Med 1998;158:1950-1952
114. Fraschini G, Jadeja J, Lawson M, et al. Local infusion of urokinase for the lysis of thrombosis associated with permanent central venous catheters in cancer patients. J Clin Oncol 1987;5:672-678
115. Schwarz RE, Marrero AM, Conlon KC, Burr M. Inferior vena cava filters in cancer patients: indications and outcomes. J Clin Oncol 1996;14:652-657
116. Ihnat DM, Mills JL, Hughes JD, et al. Treatment of patients with venous thromboembolism and malignant disease: should vena cava filter placement be routine? J Vasc Surg 1998;28:800-807
117. Streift MB. Vena cava filters: a comprehensive review. Blood 2000;95:3669-3677
118. Athanasoulis CA, Kaufman JA, Halpern EF, et al. Inferior vena caval filters; a review of a 26-year single-centre clinical experience. Radiology 2000;21:54-66
119. Millward SF, Peterson RA, Moher D, et al. LGM (Vena Tech) vena caval filter: experience at a single institution. J Vasc Interv Radiol 1994;5:351-356
120. Spence LD, Gironta MG, Malde HM, et al. Acute upper extremity deep venous thrombosis: safety and effectiveness of superior vena caval filters. Radiology 1999;210: 53-58
121. Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. N Engl J Med 1998;338:409-41573